CEPI Expands its Investment in the Development of Vaccine Against COVID-19

 CEPI Expands its Investment in the Development of Vaccine Against COVID-19

CEPI Expands its Investment in the Development of Vaccine Against COVID-19

Shots:

  • CEPI to provide $4.4M to Novavax & the University of Oxford for accelerating the development of vaccines against COVID-19. CEPI has invested up to $23.7M in R&D of COVID-19 vaccines
  • Novavax is assessing multiple nanoparticle vaccine candidates to identify the best candidates for clinical studies. CEPI will provide the initial funding to Novavax for the initiation of P-I study, which is expected to be initiated in H1’20
  • The company has developed the vaccine candidates using its recombinant protein nanoparticle technology to generate antigens derived from the coronavirus spike protein and is expected to utilize its Matrix-M adjuvant to enhance the immune response of vaccine candidates

Source 1, Source 2 ­to­ read full press release/ article | Ref: CEPI, GlobeNewswire | Image: CEPI

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post